Biodesix to Participate in Three Investor Conferences in November

Core Insights - Biodesix, Inc. is a leading diagnostic solutions company focused on lung disease, with upcoming participation in three investor conferences in New York City [1] Group 1: Upcoming Investor Conferences - Scott Hutton, CEO, and Robin Cowie, CFO of Biodesix, will participate in the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024 [1] - The Wolfe Research Healthcare Conference 2024 will also feature 1x1 meetings on November 20, 2024 [1] - Biodesix will present at the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on November 21, 2024, at 1:00 PM ET, with a live webcast available [1] Group 2: Company Overview - Biodesix offers five Medicare-covered tests for lung diseases, including the blood-based Nodify Lung® Nodule Risk Assessment and the IQLung™ test portfolio for lung cancer patients [2] - The Nodify Lung® tests help evaluate the risk of malignancy in pulmonary nodules, aiding physicians in patient triage [2] - The IQLung™ test portfolio supports treatment decisions across all stages of lung cancer and aims to expedite personalized treatment [2] - The company collaborates with leading biopharmaceutical companies for biomarker discovery, diagnostic test development, and clinical trial support [2]